8.5.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
8.5.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
8.6 Global Gastrointestinal Therapeutics Market - Opportunity Analysis Index,
By Drug Class,
By Indication,
By End User,
and Region, 2024 - 2031
9. North America Global Gastrointestinal Therapeutics Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
9.1 By Drug Class Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
9.1.1 Aminosalicylates
9.1.2 Antacids
9.1.3 Antidiarrheals
9.1.4 Antiemetics
9.1.5 Antiulcer Agents
9.1.6 Biologics
9.1.7 Laxatives
9.1.8 Proton Pump Inhibitors (PPIs)
9.1.9 H2 Receptor Antagonists
9.1.10 Prokinetics
9.1.11 Antibiotics
9.2 By Indication Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
9.2.1 Gastroesophageal Reflux Disease (GERD)
9.2.2 Peptic Ulcer Disease
9.2.3 Irritable Bowel Syndrome (IBS)
9.2.4 Inflammatory Disease (IBD)
9.2.5 Diarrhea
9.2.6 Constipation
9.2.7 Nausea and Vomiting
9.2.8 Celiac Disease
9.2.9 Others
9.3 By End User Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
9.3.1 Hospitals
9.3.2 Clinics
9.3.3 Homecare Settings
9.3.4 Ambulatory Surgical Centers.
9.4 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
9.4.1 United States
9.4.2 Canada
9.5 North America
Global Gastrointestinal Therapeutics Market – Opportunity Analysis Index,
By Drug Class,
By Indication,
By End User,
and Country, 2024 - 2031
9.6 Regional Trends Analysis
9.7 North America Global Gastrointestinal Therapeutics Market Research Report - Company Profiles
9.7.1 Company 1 (United States)
9.7.2 Company 2 (Canada)
9.7.3 Company 3 (Canada)
10. Europe Global Gastrointestinal Therapeutics Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
10.1 By Drug Class Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
10.1.1 Aminosalicylates
10.1.2 Antacids
10.1.3 Antidiarrheals
10.1.4 Antiemetics
10.1.5 Antiulcer Agents
10.1.6 Biologics
10.1.7 Laxatives
10.1.8 Proton Pump Inhibitors (PPIs)
10.1.9 H2 Receptor Antagonists
10.1.10 Prokinetics
10.1.11 Antibiotics
10.2 By Indication Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
10.2.1 Gastroesophageal Reflux Disease (GERD)
10.2.2 Peptic Ulcer Disease
10.2.3 Irritable Bowel Syndrome (IBS)
10.2.4 Inflammatory Disease (IBD)
10.2.5 Diarrhea
10.2.6 Constipation
10.2.7 Nausea and Vomiting
10.2.8 Celiac Disease
10.2.9 Others
10.3 By End User Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
10.3.1 Hospitals
10.3.2 Clinics
10.3.3 Homecare Settings
10.3.4 Ambulatory Surgical Centers.
10.4 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
10.4.1 Germany
10.4.2 United Kingdom
10.4.3 France
10.4.4 Spain
10.4.5 Italy
10.4.6 Russia
10.4.7 Netherlands
10.4.8 Poland
10.4.9 Rest of Europe
10.5 Europe
Global Gastrointestinal Therapeutics Market – Opportunity Analysis Index,
By Drug Class,
By Indication,
By End User,
and Country, 2024 - 2031
10.6 Regional Trends Analysis
10.7 Europe Global Gastrointestinal Therapeutics Market Research Report - Company Profiles
10.7.1 Company 1 (Germany)
10.7.2 Company 2 (United Kingdom)
10.7.3 Company 3 (United Kingdom)
11. Asia-Pacific Global Gastrointestinal Therapeutics Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
11.1 By Drug Class Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
11.1.1 Aminosalicylates
11.1.2 Antacids
11.1.3 Antidiarrheals
11.1.4 Antiemetics
11.1.5 Antiulcer Agents
11.1.6 Biologics
11.1.7 Laxatives
11.1.8 Proton Pump Inhibitors (PPIs)
11.1.9 H2 Receptor Antagonists
11.1.10 Prokinetics
11.1.11 Antibiotics
11.2 By Indication Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
11.2.1 Gastroesophageal Reflux Disease (GERD)
11.2.2 Peptic Ulcer Disease
11.2.3 Irritable Bowel Syndrome (IBS)
11.2.4 Inflammatory Disease (IBD)
11.2.5 Diarrhea
11.2.6 Constipation
11.2.7 Nausea and Vomiting
11.2.8 Celiac Disease
11.2.9 Others
11.3 By End User Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
11.3.1 Hospitals
11.3.2 Clinics
11.3.3 Homecare Settings
11.3.4 Ambulatory Surgical Centers.
11.4 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
11.4.1 China
11.4.2 Japan
11.4.3 India
11.4.4 South Korea
11.4.5 Australia & NZ
11.4.6 ASEAN
11.4.7 Rest of Asia-Pacific
11.5 Asia-Pacific
Global Gastrointestinal Therapeutics Market – Opportunity Analysis Index,
By Drug Class,
By Indication,
By End User,
and Country, 2024 - 2031
11.6 Regional Trends Analysis
11.7 Asia-Pacific Global Gastrointestinal Therapeutics Market Research Report - Company Profiles
11.7.1 Company 1 (China)
11.7.2 Company 2 (Japan)
11.7.3 Company 3 (Japan)
12. Latin America Global Gastrointestinal Therapeutics Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
12.1 By Drug Class Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
12.1.1 Aminosalicylates
12.1.2 Antacids
12.1.3 Antidiarrheals
12.1.4 Antiemetics
12.1.5 Antiulcer Agents
12.1.6 Biologics
12.1.7 Laxatives
12.1.8 Proton Pump Inhibitors (PPIs)
12.1.9 H2 Receptor Antagonists
12.1.10 Prokinetics
12.1.11 Antibiotics
12.2 By Indication Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
12.2.1 Gastroesophageal Reflux Disease (GERD)
12.2.2 Peptic Ulcer Disease
12.2.3 Irritable Bowel Syndrome (IBS)
12.2.4 Inflammatory Disease (IBD)
12.2.5 Diarrhea
12.2.6 Constipation
12.2.7 Nausea and Vomiting
12.2.8 Celiac Disease
12.2.9 Others
12.3 By End User Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
12.3.1 Hospitals
12.3.2 Clinics
12.3.3 Homecare Settings
12.3.4 Ambulatory Surgical Centers.
12.4 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
12.4.1 Brazil
12.4.2 Mexico
12.4.3 Argentina
12.4.4 Peru
12.4.5 Colombia
12.4.6 Rest of Latin America
12.5 Latin America
Global Gastrointestinal Therapeutics Market – Opportunity Analysis Index,
By Drug Class,
By Indication,
By End User,
and Country, 2024 - 2031
12.6 Regional Trends Analysis
12.7 Latin America Global Gastrointestinal Therapeutics Market Research Report - Company Profiles
12.7.1 Company 1 (Brazil)
12.7.2 Company 2 (Mexico)
12.7.3 Company 3 (Mexico)
13. Middle East & Africa Global Gastrointestinal Therapeutics Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
13.1 By Drug Class Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
13.1.1 Aminosalicylates
13.1.2 Antacids
13.1.3 Antidiarrheals
13.1.4 Antiemetics
13.1.5 Antiulcer Agents
13.1.6 Biologics
13.1.7 Laxatives
13.1.8 Proton Pump Inhibitors (PPIs)
13.1.9 H2 Receptor Antagonists
13.1.10 Prokinetics
13.1.11 Antibiotics
13.2 By Indication Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
13.2.1 Gastroesophageal Reflux Disease (GERD)
13.2.2 Peptic Ulcer Disease
13.2.3 Irritable Bowel Syndrome (IBS)
13.2.4 Inflammatory Disease (IBD)
13.2.5 Diarrhea
13.2.6 Constipation
13.2.7 Nausea and Vomiting
13.2.8 Celiac Disease
13.2.9 Others
13.3 By End User Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
13.3.1 Hospitals
13.3.2 Clinics
13.3.3 Homecare Settings
13.3.4 Ambulatory Surgical Centers.
13.4 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
13.4.1 Saudi Arabia
13.4.2 UAE
13.4.3 South Africa
13.4.4 Egypt
13.4.5 Israel
13.4.6 Rest of Middle East and Africa
13.5 Middle East & Africa
Global Gastrointestinal Therapeutics Market – Opportunity Analysis Index,
By Drug Class,
By Indication,
By End User,
and Country, 2024 - 2031
13.6 Regional Trends Analysis
13.7 Middle East & Africa Global Gastrointestinal Therapeutics Market Research Report - Company Profiles
13.7.1 Company 1 (Saudi Arabia)
13.7.2 Company 2 (UAE)
13.7.3 Company 3 (UAE)
14. Competition Landscape
14.1 Strategic Dashboard of Top Market Players
14.2 Company Profiles (Introduction, Financial Assessments, Portfolio of Offerings, Milestones and Achievements, Strategic Initiative, and SWOT Analysis)
14.2.1 AbbVie Inc.
14.2.2 Takeda Pharmaceutical Company Limited
14.2.3 Johnson & Johnson
14.2.4 Pfizer Inc.
14.2.5 GlaxoSmithKline plc
15. Data Collection Method and Research Approach 16. Principal Presumptions and Acronyms
Methodology & Credibility
Built for enterprise decisions, not vanity metrics.
Triangulated Sizing
Bottom-up, top-down, and peer benchmarks reconciled by analysts.
Primary + Secondary Research
Executive interviews combined with validated public and paid sources.
Scenario & Sensitivity
Base, bull and bear cases to stress-test strategic moves.
Need Confidence Fast?
We’ll map your questions to the report in 15 minutes.
